Screening Adults for Type 2 Diabetes: A Cost-effectiveness Analysis. Appendix Table 1. Base-Case Values and Distributions Applied in Probabilistic Sensitivity Analysis for Selected Parameters: Diabetes Screening

You Are Here: AHRQ Home > Clinical Information > U.S. Preventive Services Task Force (USPSTF) > Guide to Clinical Preventive Services, 2001-2004 > Screening: Type 2 Diabetes > Cost-effectiveness Analysis

Appendix Table 1. Base-Case Values and Distributions Applied in Probabilistic Sensitivity Analysis for Selected Parameters: Diabetes Screening

Parameter				Parameter Value		Base-Case Source
Parameter				Base-Case Analysis^a	Probabilistic Sensitivity Analysis Distribution^b	Base-Case Source
Prevalence of undiagnosed diabetes, %	Non-hypertensive		Ages 0 to 49 y	5.534	Logn(5.53, 3.61)	36
			50 to 59 y	5.742	Logn(5.74, 3.26)	36
			60 to 69 y	2.606	Logn(2.61, 0.96)	36
			70 to 94 y	4.779	Logn(4.78, 3.07)	36
	Hypertensive		Ages 0 to 49 y	5.302	Logn(5.30, 2.71)	36
			50 to 59 y	8.178	Logn(8.18, 5.09)	36
			60 to 69 y	3.403	Logn(3.40, 1.70)	36
			70 to 94 y	4.047	Logn(4.05, 2.55)	36
Sensitivity and specificity of capillary blood glucose (CBG) test for identifying diabetes	Sensitivity	Female	Ages 0 to 44 y	0.973	Logn(0.973, 0.954)	22
		Female	45 to 94 y	0.796	Logn(0.796, 0.780)	22
		Male	Ages 0 to 44 y	0.961	Logn(0.961, 0.942)	22
		Male	45 to 94 y	0.938	Logn(0.938, 0.919)	22
	Specificity	Female	Ages 0 to 44 y	0.740	Logn(0.740, 0.725)	22
		Female	45 to 94 y	0.928	Logn(0.928, 0.909)	22
		Male	Ages 0 to 44 y	0.912	Logn(0.912, 0.894)	22
		Male	45 to 94 y	0.905	Logn(0.905, 0.887)	22
Transition probabilities	Normal to microalbuminuria			0.0113	Not varied	37
Transition probabilities	Normal to peripheral neuropathy			0.0036	Not varied	37
Costs	Screening test (CBG)			$4.37	Triang(3.28, 4.37, 5.46)	23
	Diagnostic test (Fasting Plasma Glucose)			$5.32	Triang(3.99, 5.32, 6.65)	23
	Blood draw (for diagnostic test)			$3.00	Triang(2.25, 3.00, 3.75)	23
	15-min physician visit			38.63	Triang(29, 39, 48)	23
	25-min physician visit (extra 10 mins for screen)			58.66	Triang(44, 59, 73)	23
Other	Time from diabetes onset to screening, y			5	Unif(4.00, 6.00)	Assumed
Other	Time from diabetes onset to diagnosis, y			10	Unif(9, 12)	15

^a These values were applied in all model runs unless otherwise specified (in one-way and probabilistic sensitivity analyses).
^b The distributions from which parameter values were randomly sampled in the probabilistic sensitivity analyses. The ranges for parameters without published variability data followed these guidelines: screening sensitivity and specificity values vary by +/- 2%; costs more than $300 vary by +/-15%; costs less than $300, time durations, transition probabilities, hazard rates, and quality-of-life values vary by +/-25%; and the discounting factor varies from 2% to 5%. Relevant limits were applied to all ranges (e.g., quality of life and probabilities must be between 0 and 1).

Note: Logn(a,b) = Lognormal distribution with mean a, lower bound of 95% confidence interval b; Triang(a,b,c) = Triangular distribution with minimum a, mode b, maximum c. Unif(a,b) = Uniform distribution with minimum a, maximum b.

Return to Document
Proceed to Appendix Table 2. Discount Rates